Combination of Gemcitabine and Docetaxel in Management of Leiomyosarcoma Metastasis

2017 ◽  
Vol 1 (2) ◽  
pp. AY1-AY2
Author(s):  
Monali Rajawat
Keyword(s):  
Small Intestine ◽  
Radiofrequency Ablation ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Combination Therapy ◽  
Genetic Factors ◽  
Target Therapy ◽  
Treatment Options ◽  
Main Route

Leiomyosarcoma is a type of a soft tissue sarcoma which is one of the rarest tumor found in the human mankind. It is predominantly localized either in stomach, small intestine or retroperitoneum and often metastasizes to the distant parts like the lungs or liver. The main route of the metastasis is via the bloodstream, however, the lymphatics could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet unknown to men, but few studies has shown that genetic factors have an important role to play. The treatment options available for LMS metastasis (mets) in liver are very limited which ranges from chemotherapy, radiofrequency ablation and target therapy. Here I discuss a case of LMS mets to the liver managed by a combination therapy of Gemcitabine and Docetaxel.

scholarly journals Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jana Käthe Striefler ◽  
Franziska Brandes ◽  
Alexander Baur ◽  
Berit Maria Pfitzner ◽  
David Kaul ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Combination Therapy ◽  
Single Centre ◽  
Single Centre Experience ◽  
Metastatic Soft Tissue Sarcoma

scholarly journals Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft-Tissue Sarcoma: A Meta-Analysis and Clinical Practice Guideline

Sarcoma ◽  
2000 ◽  
Vol 4 (3) ◽  
pp. 103-112 ◽  
Author(s):  
Vivien H. C. Bramwell ◽  
Dale Anderson ◽  
Manya L. Charette
Keyword(s):  
Overall Survival ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Meta Analysis ◽  
Single Agent ◽  
Locally Advanced ◽  
Metastatic Soft Tissue Sarcoma ◽  
Single Agent Chemotherapy

Purpose.To make recommendations for the use of doxorubicin-based chemotherapy in patients with soft-tissue sarcoma.Patients.The recommendations apply to patients with symptomatic unresectable locally advanced or metastatic soft-tissue sarcoma who are candidates for palliative chemotherapy.Methods.A systematic review of the published literature was combined with a consensus process around the interpretation of the evidence in the context of conventional practice to develop an evidence-based practice guideline.Results.Eight randomized trials comparing doxorubicin-based combination versus doxorubicin single-agent chemotherapy were reviewed. Response rates and overall survival were evaluated using pooled statistical analysis.The pooled response data in 2281 patients showed a slight trend favouring the combination therapy, although this did not reach statistical significance (odds ratio (OR), 0.79; 95% confidence interval (CI), 0.60–1.05;p=0.10). Survival data could only be abstracted from six studies involving 2097 patients, and showed no significant advantage for combination therapy (OR, 0.84; 95% CI, 0.67–1.06;p=0.13). Data on adverse effects could not be combined in a meta-analysis; however nausea, vomiting and myelosuppression were consistently more severe with combination chemotherapy than with single-agent chemotherapy.Discussion.Single-agent doxorubicin is an appropriate first-line chemotherapy option for advanced or metastatic soft-tissue sarcoma. Some doxorubicin-based combination chemotherapy regimens, given in conventional doses, produce only marginal increases in response rates, at the expense of increased adverse effects, and with no improvements in overall survival. Future randomized clinical trials should compare new regimens, whose activity has been established in single-arm studies, with single-agent doxorubicin, and include quality of life as an outcome measure.

scholarly journals Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

2016 ◽  
Vol Volume 8 ◽  
pp. 95-104 ◽  
Author(s):  
Winette van der Graaf ◽  
Ingrid Desar ◽  
Anastasia Constantinidou ◽  
Suzanne Kaal ◽  
Robin Jones
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Critical Appraisal ◽  
Treatment Options ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250643
Author(s):  
Toshinori Omori ◽  
Hiroshi Tazawa ◽  
Yasuaki Yamakawa ◽  
Shuhei Osaki ◽  
Joe Hasei ◽  
...  
Keyword(s):  
Dna Damage ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Ionizing Radiation ◽  
Combination Therapy ◽  
Cell Lines ◽  
Antitumor Effect ◽  
Therapeutic Potential ◽  
Subcutaneous Xenograft ◽  
Induced Apoptosis

Soft tissue sarcoma (STS) is a rare cancer that develops from soft tissues in any part of the body. Despite major advances in the treatment of STS, patients are often refractory to conventional radiotherapy, leading to poor prognosis. Enhancement of sensitivity to radiotherapy would therefore improve the clinical outcome of STS patients. We previously revealed that the tumor-specific, replication-competent oncolytic adenovirus OBP-301 kills human sarcoma cells. In this study, we investigated the radiosensitizing effect of OBP-301 in human STS cells. The in vitro antitumor effect of OBP-301 and ionizing radiation in monotherapy or combination therapy was assessed using highly radiosensitive (RD-ES and SK-ES-1) and moderately radiosensitive (HT1080 and NMS-2) STS cell lines. The expression of markers for apoptosis and DNA damage were evaluated in STS cells after treatment. The therapeutic potential of combination therapy was further analyzed using SK-ES-1 and HT1080 cells in subcutaneous xenograft tumor models. The combination of OBP-301 and ionizing radiation showed a synergistic antitumor effect in all human STS cell lines tested, including those that show different radiosensitivity. OBP-301 was found to enhance irradiation-induced apoptosis and DNA damage via suppression of anti-apoptotic myeloid cell leukemia 1 (MCL1), which was expressed at higher levels in moderately radiosensitive cell lines. The combination of OBP-301 and ionizing radiation showed a more profound antitumor effect compared to monotherapy in SK-ES-1 (highly radiosensitive) and HT1080 (moderately radiosensitive) subcutaneous xenograft tumors. OBP-301 is a promising antitumor reagent to improve the therapeutic potential of radiotherapy by increasing radiation-induced apoptosis in STS.

scholarly journals Study of soft tissue sarcomas over a period of 3 years

2017 ◽  
Vol 5 (6) ◽  
pp. 2678 ◽  
Author(s):  
Jenna Prabhakar ◽  
J. Sushma ◽  
B. V. S. Kartheek ◽  
A. Bhagya Lakshmi ◽  
Chapara Vaibhav
Keyword(s):  
Soft Tissue ◽  
Health Education ◽  
Soft Tissue Sarcoma ◽  
Treatment Options ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Mesenchymal Cell ◽  
Histological Type ◽  
Treatment Modalities ◽  
Site Distribution

Background: Soft tissue malignancies constituted a heterogeneous group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathological features. The aim of the study was to know the prevalence of soft tissue sarcoma, sex, age and site distribution, histopathology and various treatment options adopted with follow up.Methods: A total of 26 cases of soft tissue sarcoma were analyzed for a three-year period. Clinical presentation, age and sex distribution, histological type and treatment modalities adopted were recorded and analyzed.Results: Out of 26 cases 44% of cases were between 30-50 years and 44% of tumors were situated in lower extremity. The commonest histological type was liposarcomas and fibrosarcoma. Lymph node metastasis was seen in 4% of cases. Distant metastasis was present in 3 cases, 2 with lung metastasis and l with lung and liver metastasis. Surgery was the main modality of the treatment. 12% of the cases presented with recurrent tumor, the duration between surgery and recurrence was 6 months. Only 38% turned for follow up, 2 patients succumbed to death because of multiple pulmonary secondaries and chest infections.Conclusion: In the present study, all the cases of soft tissue sarcoma presented in late stage of the disease due to illiteracy and lack of health education. Recurrence was seen in 12% of cases. The overall survival rates and quality of life of the patients can be improved by frequent health camps at primary health centers for early detection of the disease, providing adequate health education, diagnostic and management facilities.

scholarly journals Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Shoko Marshall ◽  
Kenji Nakano ◽  
Yoshiya Sugiura ◽  
Shinichiro Taira ◽  
Makiko Ono ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Combination Therapy ◽  
Response Rate ◽  
Overall Response ◽  
Institutional Review ◽  
Significant Difference ◽  
Bulky Mass

Background. Doxorubicin is the key drug for treatment of advanced soft tissue sarcoma (STS). The appropriate dosage of doxorubicin, regarding monotherapy or the role of combination therapy, is unclear. Methods. We retrospectively reviewed patients with advanced or metastatic STS of nonextremities who were treated with doxorubicin-based chemotherapies in our institution. Time to treatment failure (TTF), overall survival (OS), overall response, and prognostic factors for OS were evaluated. Results. Seventy-five patients were enrolled. The median TTF was 4.7 months, and the median OS was 20.1 months. The overall response rate was 20%. Doses of doxorubicin monotherapy did not show significant difference either in TTF or in OS. There were no significant differences in OS between combination therapy and monotherapy, but the TTF with combination therapy was better than monotherapy. The overall response for combination therapy indicated a better response rate. Less number of involved organs, no bulky mass, and a normal CRP level were independent favorable prognostic factors for OS. Conclusions. Combination therapy showed better response and TTF than monotherapy but did not show better OS. Possible prognostic factors for OS were indicated. This retrospective study was approved by the institutional review board. This trial is registered with UMIN000028787.

Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e23550-e23550
Author(s):  
Nail Paksoy ◽  
Izzet Dogan ◽  
Meltem Ekenel ◽  
Mert Basaran
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Metastatic Disease ◽  
De Novo ◽  
Treatment Options ◽  
Palliative Radiotherapy ◽  
Progression Free Survival ◽  
Primary Treatment Modality ◽  
Heavily Pretreated ◽  
Metastatic Sarcoma

e23550 Background: Sarcoma is a rare heterogeneous group malignancy and most commonly arises from soft tissue. The primary treatment modality is surgery. However, in metastatic disease, treatment options are limited. Cytotoxic chemotherapy is preferred for palliative treatment. This study aimed to assess the efficacy of temozolomide in heavily pretreated soft tissue sarcoma. Methods: We evaluated the patients with a metastatic various types of soft tissue sarcoma retrospectively. The patients with gastrointestinal stromal tumors and bone sarcomas were excluded from the study. We recorded the clinical, pathological, and treatment data of the patients. SPSS 25v was used for statistical analysis. Survival analysis was performed with the Kaplan-Meier method. Results: Sixteen patients were included in this study. The median age was 48 (range, 21-73) years. Six (37.5%) patients were de-novo metastatic. Tumor localizations were intra-abdominal (43.8%), extremity (31.2%), intrathoracic (12.5%), and head-and-neck (12.5%). The most common metastatic sites were lung (75%), bone (31.8%), liver (18.8%), respectively. For metastatic disease, the patients received at least two different chemotherapy regimens (75%), pazopanib (50%) and palliative radiotherapy (31.3%). Metastasectomy was also performed on five (31.3%) patients. Median progression-free survival was 3.5 (95% CI, 2.6-4.3) months. Partial response was observed in one (6.3%) patients, stable disease in four (25 %) patients. Eleven (68.8%) patients had progressive disease. Grade 1-2 adverse events were observed in nine (56.3%) patients, grade 3-4 in one (6.3%) patients. Conclusions: We showed that temozolomide was well-tolerated but had a limited efficacy for the treatment of patients with metastatic sarcoma. Treatment options for metastatic sarcomas are limited. Temozolomide may be considered a treatment option in patients with heavily pretreated soft tissue sarcoma.

scholarly journals Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

2017 ◽  
Vol 9 (8) ◽  
pp. 533-550 ◽  
Author(s):  
Gino K. In ◽  
James S. Hu ◽  
William W. Tseng
Keyword(s):  
Overall Survival ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Alkylating Agents ◽  
Treatment Options ◽  
Cytotoxic Agents ◽  
High Grade ◽  
Metastatic Setting ◽  
Line Setting ◽  
New Treatments

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefit beyond the first-line setting; across all high-grade STS subtypes, median overall survival remains approximately 12–18 months for advanced metastatic disease. The development of targeted therapies has led to recent US Food and Drug Administration approval of four new treatments for high-grade STS in the advanced metastatic setting. Among these, olaratumab is most notable for its improvement in overall survival for patients with anthracycline-naïve disease. Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.

scholarly journals Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease

2014 ◽  
Vol 37 (6) ◽  
pp. 355-362 ◽  
Author(s):  
Patrick Schöffski ◽  
Jasmien Cornillie ◽  
Agnieszka Wozniak ◽  
Haifu Li ◽  
Daphne Hompes
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Treatment Options
Sign in / Sign up

Export Citation Format

Share Document